Calidi Biotherapeutics Advances Cancer Treatment Platform with Innovative Immunotherapy Approach
Calidi Biotherapeutics has developed a novel systemic antitumor virotherapy platform that delivers an IL15 superagonist directly into tumor microenvironments, potentially revolutionizing metastatic cancer treatment by boosting immune response while minimizing systemic toxicity.
Biotechnology company Calidi Biotherapeutics has announced a significant advancement in cancer treatment through its RTNova platform, selecting an IL15 superagonist as its first therapeutic payload. The platform represents a breakthrough in targeted immunotherapy, with preclinical data demonstrating the potential to enhance tumor elimination while reducing widespread side effects.
The company's engineered vaccinia virus can deliver the IL15 superagonist (IL15-IL15Ra) directly into tumor microenvironments, which could dramatically improve how metastatic cancers are treated. Preclinical research presented at the American Association for Cancer Research (AACR) Annual Meeting highlighted the platform's ability to significantly boost immune response against tumors.
This innovation addresses a critical challenge in cancer treatment: targeting malignant cells effectively without causing extensive damage to healthy tissue. By enabling systemic delivery of tumor-targeted virotherapies, Calidi Biotherapeutics' platform offers a promising approach to treating challenging metastatic cancers.
The RTNova platform's unique design allows for a dual approach that could potentially not only treat existing metastatic disease but also help prevent its spread. This represents a substantial leap forward in oncological research, offering hope for more precise and less invasive cancer therapies.